Once a day vs multiple doses a day regimen of gentamicin for treatment of suspected or proven sepsis in neonates

Rao, SC; Ahmed, Mohmed; Hagan, R. D.

doi:10.1002/14651858.cd005091

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Late onset sepsis (LOS) is another common life-threatening disease for preterm infants. It is commonly defined as a systemic infection with the isolation of pathogenic bacteria from the bloodstream after 72 h of life (Rao, Ahmed & Hagan, 2016; Pickering, Baker & Kimberlin, 2012). Preterm infants have immature gastrointestinal and immune systems.…”

Section: Introductionmentioning

confidence: 99%

Patterned progression of gut microbiota associated with necrotizing enterocolitis and late onset sepsis in preterm infants: a prospective study in a Chinese neonatal intensive care unit

Liu

Feng

et al. 2019

PeerJ

View full text Add to dashboard Cite

Necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) are two common premature birth complications with high morbidity and mortality. Recent studies in Europe and America have linked gut microbiota dysbiosis to their etiology. However, similar studies in Asian populations remain scant. In this pilot study, we profiled gut microbiota of 24 Chinese preterm infants from birth till death or discharge from NICU. Four of them developed NEC and three developed LOS. Unexpectedly, we detected highly-diversified microbiota with similar compositions in all patients shortly after birth. However, as patients aged, the microbial diversities in case groups differed significantly from that of the control group. These differences emerged after the third day of life and persisted throughout the course of both NEC and LOS. Using a Zero-Inflated Beta Regression Model with Random Effects (ZIBR), we detected higher Bacillus (p = 0.032) and Solibacillus (p = 0.047) before the onset of NEC and LOS. During NEC progression, Enterococcus, Streptococcus and Peptoclostridium were the dominant genera while during LOS progression; Klebsiella was the only dominant genus that was also detected by the diagnostic hemoculture. These results warrant further studies to identify causative microbial patterns and underlying mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Patterned progression of gut microbiota associated with necrotizing enterocolitis and late onset sepsis in preterm infants: a prospective study in a Chinese neonatal intensive care unit

Liu

Feng

et al. 2019

PeerJ

View full text Add to dashboard Cite

show abstract

“…GEN is a potent aminoglycoside antibiotic with bactericidal activity against Gram-negative bacteria and is widely utilized due to its efficacy and low cost (4). Similar to other aminoglycosides, GEN has a narrow therapeutic index and has the potential for ototoxicity and nephrotoxicity (5, 6). GEN is excreted in the kidneys primarily by glomerular filtration and has a short plasma elimination half-life in healthy individuals presenting with normal renal function (7).…”

Section: Introductionmentioning

confidence: 99%

Control of Klebsiella pneumoniae Infection in Mice by Using Dissolving Microarray Patches Containing Gentamicin

Rodgers

McCrudden

Courtenay

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Ototoxic Drug Exposure and Hearing Loss in Neonates: A Scoping Review

Rameshsankar,

Seethapathy,

Balakrishnan

2024

Am J Audiol

View full text Add to dashboard Cite

Purpose: This scoping review aims to map the effects of dosage levels, dosage intervals, duration of exposure, and serum concentration levels of gentamicin, amikacin, vancomycin, furosemide, and bumetanide on newborn hearing. Method: Using PubMed, Scopus, and Ovid databases (January 2010–2022), a scoping review was conducted to identify studies on ototoxic drug exposure in neonates. The review included articles that described details on ototoxic drug exposure and hearing status, dosage levels, duration of exposure, and serum concentration levels. The search results were summarized using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. Results: Out of 4,395 entries, 28 were selected for inclusion in the scoping review. The studies were separated according to the exposed drugs: gentamicin, amikacin, vancomycin, furosemide, bumetanide, and a combination of drugs. Four out of five studies on amikacin exposure revealed an increased association with ototoxicity and abnormal trough levels. Six of seven studies on gentamicin exposure reported elevated trough concentration levels in a small number of infants, but no studies reported hearing loss. Two out of four studies on vancomycin exposure reported a dose-dependent risk for infants to develop hearing loss. Conclusions: Gentamicin exposure in neonates has been extensively studied and considered relatively safe, except in cases of elevated peak or trough concentration levels. Amikacin exposure was reported to be more ototoxic, as the elevation of trough concentration levels was associated with refer results in hearing. Loop-diuretic exposure demonstrated a significant ototoxic effect. When used with other ototoxic medications, vancomycin is said to have a greater effect on ototoxicity. Supplemental Material: https://doi.org/10.23641/asha.26814700

show abstract

Once a day vs multiple doses a day regimen of gentamicin for treatment of suspected or proven sepsis in neonates

Cited by 3 publications

References 18 publications

Patterned progression of gut microbiota associated with necrotizing enterocolitis and late onset sepsis in preterm infants: a prospective study in a Chinese neonatal intensive care unit

Patterned progression of gut microbiota associated with necrotizing enterocolitis and late onset sepsis in preterm infants: a prospective study in a Chinese neonatal intensive care unit

Control of Klebsiella pneumoniae Infection in Mice by Using Dissolving Microarray Patches Containing Gentamicin

Ototoxic Drug Exposure and Hearing Loss in Neonates: A Scoping Review

Contact Info

Product

Resources

About